You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. NarcoBond: Opioid Targeted Biomimetic Nanosponges for Treatment of Opioid Overdose

    SBC: CiBots            Topic: NIDA

    Abstract We propose to develop a broad acute/sub-acute opioid drug detoxifying treatment for opioid overdose that can complement andamp; compensate for the deficiencies in nalaxone, using opioid-targeted biomimetic “nanosponges” that absorb overdosed opioids in the body. (Note: if this proof-of-concept is successful here, the approach may be tailored to other drugs-of-abuse.) Called “NarcoBo ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain

    SBC: Abalone Bio, Inc.            Topic: 102

    SummaryTherapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain Chroniclife disrupting painsuch as allodynia from chemotherapy induced peripheral neuropathyCIPNis difficult to manageIn this Phase I SBIRAbalone Bio proposes to develop a first in class specific CBagonist antibody that is BOTH an effective and safe analgesic against CIPN as well as a co therapy to enable o ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A novel smartphone-based tool to quantify dual-task gait performance for concussion assessment

    SBC: Control One LLC            Topic: NINDS

    Project Summary Sport related concussions are a serious public health concern in the United Stateswithtomillion concussions reported annuallyYoung athletes who suffer a concussion experience quality of life alterationswith cognitive impairmentreduction in balance or coordinationand memory lossUnfortunatelyseveral factors limit the ability to accurately and feasibly evaluate the deleterious effects ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Highly accurate small-RNA sequencing of single cells (RealSeq-SC)

    SBC: REALSEQ BIOSCIENCES, INC.            Topic: 172

    Abstract The goal of this grant application is to develop the first commercially available library preparation kit for profiling small RNAs from single cells using NGS methods. Single-cell analyses of mRNA have allowed the identification of crucial differences between cells that were otherwise considered identical. These findings have shown that there is intrinsic “noise” in the regulation of ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes

    SBC: Epigen Biosciences, Inc.            Topic: NIDCR

    PROJECT SUMMARY Analgesia for post operative populations remains a significant health need that calls for innovative therapies which improve both safety and outcome measuresRecent FDA drug safety warnings and studies focusing on post operative analgesia have highlighted the imperative need for new approaches that can be utilized for common clinical scenariosAccordinglynovel treatment options that ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A single dose long-acting non-addictive polymer conjugate formulation of buprenorphine that provides immediate and prolonged analgesia for post-operative pain

    SBC: SERINA THERAPEUTICS INC            Topic: NINDS

    PAProject Summary Abstract SERis a long acting polymer pro drug of buprenorphine that is being developed to treat postoperative pain following major surgeries such as bunionectomyabdominoplastythoracotomy and knee and hip surgerySERhas no biological activity by itselfbut when administered in vivo by subcutaneous injection it enters the vascular compartment where a plasma esterasebutyrylcholinester ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A high oxygen capacity cell scaffold for the intravascular bioartifical pancreas (iBAP)

    SBC: Silicon Kidney            Topic: 200

    PROJECT SUMMARY TypeDiabetesT Daffects nearlymillion people in the United States overmillion people globallyA subset of patients have unstable T D because they possess poor glycemic control and severe hypoglycemia unawarenessWhile whole organ pancreas and islet transplantation can cure unstable T Dthese treatments are limited by immunosuppression therapy and scarcity of donor tissueIn contrastenca ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. An accurate, fast, and miniaturized glucose sensor for closed-loop diabetes management

    SBC: Integrated Medical Sensors            Topic: 200

    PROJECT SUMMARY The long term ​goal of this project is to develop a low-cost, user-friendly, and accurate glucose sensing solution with multisensor reliability to enable the use of closed-loop insulin delivery in an artificial pancreas. The system demonstrates fast sensor kinetics owing to small size, close proximity of sensor and related electronics, miniaturized electrodes with low capacitance ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk

    SBC: Enable Biosciences Inc.            Topic: NIDDK

    Type 1 diabetes (T1D) is a chronic autoimmune disease that affects millions of children and adults in the US. Up to 40% of T1D patients are diagnosed in the emergency room with life-threatening diabetic ketoacidosis (DKA), resulting in severe clinical complications and a substantial economic burden. Programs that screen for blood-borne markers of early-stage T1D (anti-islet cell autoantibodies) ca ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain

    SBC: Adynxx, Inc.            Topic: NINDS

    RESEARCH AND RELATED OTHER PROJECT INFORMATIONPROJECT SUMMARYABSTRACTFunding OpportunityPAPI NameMametJulienAs described by the HEAL Initiative Notice NOT NSthere currently exists an urgent unmet need for enhanced pain management in the form of safeeffectivenon opioid pain treatmentsChronic focal neuropathic painwhich includes pain etiologies such as radiculopathy and radiculitisfocal peripheral n ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government